Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

13.40 EUR

-1.11 %

5,618 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-1.11 %
-5.63 %
-5.63 %
-13.55 %
-7.27 %
+45.97 %
+222.89 %
+126.39 %
-97.79 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
96.66M EUR
Turnover
16.61K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Reduce
Target price
Updated
05.01.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 05.01.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2.
2026

Annual report '25

30.3.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
linkedin.com #neurorehabilitation #tms #prosthetics #embodiment #virtualreality... I am happy to share our latest publication, the result of an active collaboration between Technical University of Munich and the TUM Klinikum Rechts der Isar, exploring how Transcranial Magnetic Stimulation...
22 hours ago
by Hannu
10
The company is volatile. I’ll share my views from a slightly different perspective than above, reflecting particularly on the impacts of the Sinaptica collaboration in the event of success or failure. The stock price could be anything between €3 and €40 in the future. However, the...
yesterday
by Tsemi
7
These are the kind of companies where selling out completely, even for a moment, could be a mistake. With my luck, a takeover bid would come through right at that time, and that would be that. I’d probably rather trim my position if it feels that way. Wasn’t last year’s dip caused...
yesterday
by ooskari
7
To clarify, that €40 is by no means an absolute maximum. If the company starts growing at a rapid pace and Alzheimer’s treatment with Nexstim’s device breaks through, it’s possible that the company’s value could rise even close to a billion. The share price would then be approx. ...
yesterday
by Jorelyytikko
6
If you don’t want to be a paper hand, you should follow https://x.com/realroseceline. If you have been part of a growth story from an early stage at a good price, it’s worth considering tax matters, especially the deemed acquisition cost (hankintameno-olettama). There is no rush ...
yesterday
4
My view is that Nexstim hardly suffers from the turmoil in the stock market. For example, the stock didn’t really care about the situation in Ukraine. The number of devices sold is (still) counted in the dozens, and if someone wants a device, they will get it. Nexstim could thus ...
yesterday
by Jatast
4
The acquisition price paid in the past has nothing to do with current risk. Risk must always be assessed using the current share price as the starting point.
10 hours ago
by FoDel
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.